XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.2
SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)
 6 Months Ended
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition
The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three and six months ended June 30, 2024 (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
20242024
Revenue from Janssen Collaboration Agreement:
Over Time:
Research and Development Services$302 $1,273 
Clinical Supply Services— 2 
Total Revenue from Janssen Collaboration Agreement$302 $1,275 
The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three and six months ended June 30, 2024 (in thousands):
Three Months Ended
June 30, 2024		Six Months Ended
June 30, 2024
MundipharmaMelintaMundipharmaMelinta
Revenue from Collaboration, License and Purchase Agreements:
Point in Time:
Rezafungin Assets, including Sale of Intellectual Property and Inventory$20,833 $— $20,833 $— 
License of Intellectual Property - upon milestone achieved$— $— $813 $— 
Product Revenue— — 2,826 — 
Royalty Revenue11 49 37 125 
Over Time:
Research and Development Services629 140 3,895 457 
Clinical Supply Services9 — 175 — 
Transition Services91 — 91 — 
Total Revenue from Collaboration, License and Purchase Agreements$21,573 $189 $28,670 $582